title: Effect of epidermal growth factor administration on the development of mouse salivary gland carcinomas.
abstract: This study investigated whether epidermal growth factor (EGF) administration was capable of modifying salivary gland carcinogenesis. Two groups of mice were given 1 mg of 9,10-dimethyl-1,2-benzanthracene (DMBA) into the left submandibular gland, and then Group 1 mice received 2 microg of EGF and Group 2 mice received vehicle subcutaneously for 8 weeks. Mice in two other groups, 3 and 4, received either EGF or vehicle alone. Twelve weeks after the start of the experiment, the incidences of submandibular gland carcinomas in Groups 1 and 2 were 39% and 58%, respectively, although this difference was not statistically significant. Duct- and cyst-like structures and carcinomas in the left submandibular glands were weakly stained by anti-EGF receptor (EGFR) antibody. Immunoblot and reverse transcriptase polymerase chain reaction (RT-PCR) analyses revealed the expression of EGFR in the submandibular glands and carcinomas. However, EGFR was undetectable in YT cells that were derived from a submandibular gland undifferentiated carcinoma of a Group 2 mouse. These findings indicate that EGF does not promote tumor induction in mouse salivary gland carcinogenesis. This may be ascribed in part to the low expression level of EGFR in tumor cells.
authors.affiliation: Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Yura
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: J
authors.initials: J
authors.lastname: Kusaka
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Sato
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D002273:Carcinogens / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D002277:Carcinoma / Q000139:chemically induced* / Q000235:genetics; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000494:pharmacology*; D066246:ErbB Receptors / Q000032:analysis / Q000235:genetics; D005260:Female; D005455:Fluorescent Antibody Technique; D015972:Gene Expression Regulation, Neoplastic; D015151:Immunoblotting; D015994:Incidence; D007267:Injections; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014677:Pharmaceutical Vehicles; D016133:Polymerase Chain Reaction; D018987:Salivary Ducts / Q000187:drug effects; D013363:Submandibular Gland / Q000187:drug effects / Q000378:metabolism; D013365:Submandibular Gland Neoplasms / Q000139:chemically induced* / Q000235:genetics; D014407:Tumor Cells, Cultured
chemical_list: D002273:Carcinogens; D014677:Pharmaceutical Vehicles; D015127:9,10-Dimethyl-1,2-benzanthracene; D004815:Epidermal Growth Factor; D066246:ErbB Receptors